Sk Biopharmaceuticals Co Ltd Cash Flow-to-Debt Ratio
Sk Biopharmaceuticals Co Ltd cash flow-to-debt ratio. Sk Biopharmaceuticals Co Ltd (326030) has a Cash Flow-to-Debt Ratio of 0.05x as of March 2026, meaning its operating cash flow of ₩17.92 Billion could theoretically repay 0% of its total liabilities (₩388.37 Billion) in one year. Check how aggressively does Sk Biopharmaceuticals Co Ltd reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Sk Biopharmaceuticals Co Ltd (2016–2025)
Cash flow-to-debt ratio of Sk Biopharmaceuticals Co Ltd from 2016 to 2025. Historical debt coverage capacity for Sk Biopharmaceuticals Co Ltd across 10 annual periods. Check earnings quality score of Sk Biopharmaceuticals Co Ltd to evaluate the quality of earnings relative to operating cash generation.
Sk Biopharmaceuticals Co Ltd Cash Flow-to-Debt Ratio by Year (2016–2025)
Sk Biopharmaceuticals Co Ltd cash flow-to-debt ratio by year from 2016 to 2025. Year-by-year debt coverage analysis for Sk Biopharmaceuticals Co Ltd. For the full cash flow conversion analysis, see 326030 cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.47x | ₩176.33 Billion | ₩372.04 Billion | ▲ +131.2% |
| 2024 | 0.21x | ₩94.90 Billion | ₩462.83 Billion | ▲ +187.5% |
| 2023 | -0.23x | ₩-94.20 Billion | ₩402.22 Billion | ▲ +49.1% |
| 2022 | -0.46x | ₩-159.92 Billion | ₩347.68 Billion | ▲ +1.2% |
| 2021 | -0.47x | ₩-92.87 Billion | ₩199.46 Billion | ▲ +73.2% |
| 2020 | -1.74x | ₩-210.73 Billion | ₩121.17 Billion | ▼ -225.2% |
| 2019 | -0.53x | ₩-81.33 Billion | ₩152.10 Billion | ▲ +86.0% |
| 2018 | -3.83x | ₩-141.28 Billion | ₩36.91 Billion | ▼ -99.0% |
| 2017 | -1.92x | ₩-98.34 Billion | ₩51.12 Billion | ▼ -81.6% |
| 2016 | -1.06x | ₩-48.94 Billion | ₩46.21 Billion | — |